Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study

Denise A. Yardley, James Reeves, E. Claire Dees, Cynthia Osborne, Devchand Paul, Foluso Ademuyiwa, Hatem Soliman, Troy Guthrie, Jay Andersen, Lea Krekow, Janak Choksi, Brooke Daniel, Michael Danso, Anne Favret, Sanjay Oommen, Adam Brufsky, Jane L. Bromund, Yong Lin, Ayman B. Ibrahim, Paul D. Richards

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

We describe the efficacy and safety of ramucirumab with eribulin versus eribulin monotherapy as third- to fifth-line therapy in women with advanced breast cancer. The primary end point of progression-free survival was not met. Screening for brain metastases upon trial entry showed an unanticipated prevalence of asymptomatic brain disease, raising new considerations for screening in late-stage metastatic breast cancer irrespective of HER2 or hormone receptor status. Background Use of antiangiogenic agents in treatment of metastatic breast cancer (MBC) remains controversial. We evaluated the efficacy and safety of ramucirumab and eribulin versus eribulin alone as third- to fifth-line therapy in women with advanced breast cancer. Patients and Methods In this randomized (1:1), open-label, phase II study, US women aged 18 years or older with 2 to 4 previous chemotherapy regimens for locally recurrent or MBC, previous anthracycline and taxane treatment, and Eastern Cooperative Oncology Group performance status of 0 or 1 received ramucirumab with eribulin or eribulin alone in 21-day cycles (eribulin 1.4 mg/m2 intravenously on days 1 and 8; ramucirumab 10 mg/kg intravenously on day 1). Randomization was stratified according to previous antiangiogenic therapy and triple-negative status. The primary end point was progression-free survival (PFS) in the intention to treat population. Results One hundred forty-one women were randomized to ramucirumab with eribulin (n = 71) or eribulin alone (n = 70). Median PFS for ramucirumab with eribulin was 4.4 months (95% confidence interval [CI], 3.1-6.7) compared with 4.1 months (95% CI, 3.2-5.6) for eribulin (hazard ratio [HR], 0.83; 95% CI, 0.56-1.23; P = .35). Median overall survival in patients who received ramucirumab with eribulin was 13.5 months (95% CI, 10.4-17.9) compared with 11.5 months (95% CI, 9.0-17.3) in patients who received eribulin alone (HR, 0.91; 95% CI, 0.59-1.41; P = .68); objective response rate was 21% (13 of 62 patients) for the combination and 28% (17 of 60 patients) for eribulin alone. No unexpected toxicity was identified for the combination. Conclusion Ramucirumab combined with eribulin did not significantly improve PFS in advanced MBC.

Original languageEnglish
Pages (from-to)471-479.e1
JournalClinical breast cancer
Volume16
Issue number6
DOIs
StatePublished - Dec 1 2016

Keywords

  • Antiangiogenic therapy
  • Brain metastasis
  • Targeted agents
  • Triple-negative status
  • VEGFR-2

Fingerprint

Dive into the research topics of 'Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study'. Together they form a unique fingerprint.

Cite this